Vera Therapeutics (VERA) Stock Price

Vera Therapeutics Price

NASDAQ·CLOSED
32.28USD+1.02 (+3.20 %)
Market closed

Analysts set a median price target of 74.46 USD, implying 130.7% above the current price. Of 20 analysts, 17 rate the stock a buy — an overall Buy consensus. The stock trades about 51% above its 52-week low.

Vera Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Vera Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Vera Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Vera Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Vera Therapeutics Stock Price History
DateVera Therapeutics Price
8/21/202632.28 USD
8/20/202631.26 USD
8/19/202631.91 USD
8/18/202631.68 USD
8/14/202631.63 USD
8/13/202628.89 USD
8/12/202630.72 USD
8/10/202631.88 USD
8/7/202632.89 USD
8/6/202632.02 USD
8/5/202630.12 USD
8/4/202631.02 USD
8/3/202632.23 USD
7/31/202632.10 USD
7/30/202633.05 USD
7/29/202632.27 USD
7/27/202635.97 USD
7/23/202636.35 USD
7/22/202636.06 USD
7/21/202637.17 USD
7/20/202636.99 USD
7/17/202638.50 USD
7/16/202639.12 USD
7/15/202642.50 USD
7/14/202643.13 USD
7/13/202640.99 USD
7/10/202642.00 USD
7/9/202642.45 USD
7/8/202642.95 USD
7/7/202642.96 USD
7/6/202641.68 USD
7/2/202641.20 USD
7/1/202642.66 USD
6/30/202642.91 USD
6/29/202642.67 USD
6/26/202642.46 USD
6/25/202640.50 USD
6/24/202639.51 USD
6/23/202638.20 USD
6/22/202638.19 USD
6/18/202634.72 USD
6/17/202635.02 USD
6/16/202633.23 USD
6/15/202634.88 USD
6/12/202634.82 USD
6/11/202633.19 USD
6/10/202631.41 USD
6/9/202631.81 USD
6/8/202631.75 USD
6/5/202632.56 USD
6/4/202632.48 USD
6/3/202630.83 USD
6/2/202632.01 USD
6/1/202634.28 USD
5/29/202635.36 USD
5/28/202634.11 USD
5/27/202634.56 USD
5/26/202634.24 USD
5/22/202634.23 USD
5/21/202634.12 USD
5/20/202634.43 USD
5/19/202633.25 USD
5/18/202634.35 USD
5/15/202637.32 USD
5/14/202639.56 USD
5/13/202639.15 USD
5/12/202636.70 USD
5/11/202636.61 USD
5/8/202636.19 USD
5/7/202635.88 USD
5/6/202636.60 USD
5/5/202634.52 USD
5/4/202635.51 USD
5/1/202635.20 USD
4/30/202635.61 USD
4/29/202635.84 USD
4/28/202637.11 USD
4/27/202637.28 USD
4/24/202637.69 USD
4/23/202638.39 USD
4/22/202640.27 USD
4/21/202640.06 USD
4/20/202641.61 USD
4/17/202642.30 USD
4/16/202642.24 USD
4/15/202643.45 USD
4/14/202644.36 USD
4/13/202643.71 USD
4/10/202645.04 USD
4/9/202640.93 USD
4/8/202640.33 USD
4/7/202640.00 USD
4/6/202640.45 USD
4/2/202640.86 USD
4/1/202640.50 USD
3/31/202640.23 USD
3/30/202638.10 USD
3/27/202638.86 USD
3/26/202640.26 USD
3/25/202640.16 USD
3/24/202639.75 USD
3/23/202640.73 USD
3/20/202640.53 USD
3/19/202641.37 USD
3/18/202638.32 USD
3/17/202639.32 USD
3/16/202640.05 USD
3/13/202639.96 USD
3/12/202641.17 USD
3/11/202642.04 USD
3/10/202640.25 USD
3/9/202638.97 USD
3/6/202639.07 USD
3/5/202638.85 USD
3/4/202639.65 USD
3/3/202639.30 USD
3/2/202640.42 USD
2/27/202640.79 USD
2/26/202642.35 USD
2/25/202641.68 USD
2/24/202642.37 USD
2/23/202642.06 USD
2/20/202641.76 USD
2/19/202642.15 USD
2/18/202644.07 USD
2/17/202642.85 USD
2/13/202642.22 USD
2/12/202642.24 USD
2/11/202642.96 USD
2/10/202644.05 USD
2/9/202643.85 USD
2/6/202643.50 USD
2/5/202640.95 USD
2/4/202642.74 USD
2/3/202644.67 USD
2/2/202645.28 USD
1/30/202643.26 USD
1/29/202645.00 USD
1/28/202645.11 USD
1/27/202646.75 USD
1/26/202647.22 USD
1/23/202647.49 USD
1/22/202648.72 USD
1/21/202645.77 USD
1/20/202644.83 USD
1/16/202646.51 USD
1/15/202646.28 USD
1/14/202648.41 USD
1/13/202649.10 USD
1/12/202646.46 USD
1/9/202648.71 USD
1/8/202647.69 USD
1/7/202648.68 USD
1/6/202646.52 USD
1/5/202647.07 USD
1/2/202648.62 USD
12/31/202550.64 USD
12/30/202551.17 USD
12/29/202552.25 USD
12/26/202553.58 USD
12/24/202555.67 USD
12/23/202553.91 USD
12/22/202553.78 USD
12/19/202551.22 USD
12/18/202547.69 USD
12/17/202548.53 USD
12/16/202548.30 USD
12/15/202549.21 USD
12/12/202549.80 USD
12/11/202546.02 USD
12/10/202544.34 USD
12/9/202544.66 USD
12/8/202545.03 USD
12/5/202544.90 USD
12/4/202542.61 USD
12/3/202541.26 USD
12/2/202537.25 USD
12/1/202533.00 USD
11/28/202533.75 USD
11/26/202533.33 USD
11/25/202529.43 USD
11/24/202529.24 USD
11/21/202528.46 USD
11/20/202527.87 USD
11/19/202528.55 USD
11/18/202528.91 USD
11/17/202529.46 USD
11/14/202528.35 USD
11/13/202528.37 USD
11/12/202531.08 USD
11/11/202529.71 USD
11/10/202527.75 USD
11/7/202524.19 USD
11/6/202525.22 USD
11/5/202524.10 USD
11/4/202524.35 USD
11/3/202525.94 USD
10/31/202528.46 USD
10/30/202529.67 USD
10/29/202529.36 USD
10/28/202529.96 USD
10/27/202530.41 USD
10/24/202529.22 USD
10/23/202528.20 USD
10/22/202529.94 USD
10/21/202530.33 USD
10/20/202530.20 USD
10/17/202531.23 USD
10/16/202530.51 USD
10/15/202531.00 USD
10/14/202530.30 USD
10/13/202530.49 USD
10/10/202530.09 USD
10/9/202530.53 USD
10/8/202530.50 USD
10/7/202530.80 USD
10/6/202530.94 USD
10/3/202530.14 USD
10/2/202529.19 USD
10/1/202528.79 USD
9/30/202529.06 USD
9/29/202528.90 USD
9/26/202528.20 USD
9/25/202526.96 USD
9/24/202526.14 USD
9/23/202525.96 USD
9/22/202526.11 USD
9/19/202525.59 USD
9/18/202526.34 USD
9/17/202524.54 USD
9/16/202524.76 USD
9/15/202524.24 USD
9/12/202523.77 USD
9/11/202524.53 USD
9/10/202524.36 USD
9/9/202525.08 USD
9/8/202524.75 USD
9/5/202524.19 USD
9/4/202521.90 USD
9/3/202522.96 USD
9/2/202522.61 USD
8/29/202521.64 USD
8/28/202522.29 USD
8/27/202522.02 USD
8/26/202522.54 USD
8/25/202521.34 USD
Access this data via the Eulerpool API
Get Free API Key

Vera Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.86 M USD
-102.01 M USD
-95.99 M USD
Jan 1, 2024
0.00 USD
-167.17 M USD
-152.15 M USD
Jan 1, 2025
0.00 USD
-315.47 M USD
-299.62 M USD
Jan 1, 2026 (e)
25.55 M USD
-338.84 M USD
-437.83 M USD
Jan 1, 2027 (e)
234.90 M USD
-246.30 M USD
-299.77 M USD
Jan 1, 2028 (e)
610.64 M USD
20.32 M USD
-27.99 M USD
Jan 1, 2029 (e)
1.05 B USD
345.24 M USD
211.59 M USD
Jan 1, 2030 (e)
1.46 B USD
595.16 M USD
422.08 M USD

Vera Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 24, 2026, 7:52 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20192020202120222023202420252026e2027e2028e2029e2030e
–––––––0.030.260.711.141.58
––––––––725.81178.1359.9738.72
––––100.00––-6.45-0.78-0.28-0.18-0.13
-2.00-2.00-2.00-2.001.00-2.00-2.00-2.00-2.00-2.00-2.00-2.00
-11.00-53.00-34.00-90.00-102.00-167.00-315.00-338.00-246.0020.00345.00595.00
––––-10,200.00––-1,090.32-96.092.8130.2937.66
-11.00-53.00-32.00-89.00-95.00-152.00-299.00-447.00-281.0028.00285.00514.00
–381.82-39.62178.136.7460.0096.7149.50-37.14-109.96917.8680.35
64.2320.4821.2827.8044.4554.9064.2364.2364.2364.2364.2364.23
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Vera Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Vera Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Vera Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Vera Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Vera Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Vera Therapeutics stock margins

The Vera Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vera Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vera Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
100.00 %
- %
- %
Jan 1, 2022
100.00 %
- %
- %
Jan 1, 2023
100.00 %
-5,478.63 %
-5,155.21 %
Jan 1, 2024
100.00 %
- %
- %
Jan 1, 2025
100.00 %
- %
- %
Jan 1, 2026 (e)
100.00 %
-1,326.03 %
-1,713.45 %
Jan 1, 2027 (e)
100.00 %
-104.86 %
-127.62 %
Jan 1, 2028 (e)
100.00 %
3.33 %
-4.58 %

Vera Therapeutics Stock Revenue, EBIT, Earnings per Share

The Vera Therapeutics earnings per share therefore indicates how much revenue Vera Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 USD
-1.62 USD
-1.53 USD
Jan 1, 2022
0.00 USD
-3.27 USD
-3.20 USD
Jan 1, 2023
0.04 USD
-2.29 USD
-2.16 USD
Jan 1, 2024
0.00 USD
-3.05 USD
-2.77 USD
Jan 1, 2025
0.00 USD
-4.91 USD
-4.66 USD
Jan 1, 2026 (e)
0.36 USD
-5.28 USD
-6.25 USD
Jan 1, 2027 (e)
3.35 USD
-3.83 USD
-4.28 USD
Jan 1, 2028 (e)
8.72 USD
0.32 USD
-0.40 USD

Vera Therapeutics business model & stock analysis

Vera Therapeutics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Vera Therapeutics Employees
Details
Date
Vera Therapeutics Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Vera Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Vera Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Vera Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Vera Therapeutics shares outstanding

The number of shares of Vera Therapeutics was 64.23 M in 2025. This indicates how many shares Vera Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
21.28 M Stocks
Jan 1, 2022
27.80 M Stocks
Jan 1, 2023
44.45 M Stocks
Jan 1, 2024
54.90 M Stocks
Jan 1, 2025
64.23 M Stocks
Jan 1, 2026 (e)
64.23 M Stocks
Jan 1, 2027 (e)
64.23 M Stocks
Jan 1, 2028 (e)
64.23 M Stocks

Current Vera Therapeutics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
85.00 % (17)
Hold
15.00 % (3)
Sell
0.00 % (0)
12M Price Target
74.46
Last Price
32.28
Currency
USD
12M Return Potential
130.70 %
LTM Return
0 %

Vera Therapeutics Analyst Rating Actions

DateFirmActionRatingReliability
8/17/2026
Wedbush
Wedbush
MaintainedNeutral55
8/12/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
8/11/2026
Wedbush
Wedbush
MaintainedNeutral55
7/8/2026
Wedbush
Wedbush
MaintainedNeutral55
7/8/2026
TD Cowen
TD Cowen
MaintainedBuy58
7/8/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
7/8/2026
Guggenheim
Guggenheim
MaintainedBuy30
7/7/2026
B of A Securities
B of A Securities
MaintainedBuy66
5/15/2026
Evercore ISI Group
Evercore ISI Group
MaintainedOutperform62
3/11/2026
Wolfe Research
Wolfe Research
UpgradePeer PerformOutperform–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Vera Therapeutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/3/2026-1.61USD-0.00USD-2026 Q2
5/4/2026-1.35USD-0.00USD-2026 Q1
2/24/2026-1.31USD-0.00USD-2025 Q4
5/9/2024-0.54USD-0.00USD-2024 Q1
3/26/2024-0.51USD-0.00USD-2023 Q4
11/22/2022-0.74USD-0.00USD-2022 Q3

EESG©

Eulerpool ESG Scorecard© for the Vera Therapeutics stock

52/100
53
Environment
71
Social
31
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Vera Therapeutics shareholder structure

% Name
8.40909%
AVORO CAPITAL ADVISORS LLC
AVORO CAPITAL ADVISORS LLC
7.26560%
BLACKROCK, INC.
BLACKROCK, INC.
6.53153%
PRICE T ROWE ASSOCIATES INC /MD/
PRICE T ROWE ASSOCIATES INC /MD/
5.86330%
DEEP TRACK CAPITAL, LP
DEEP TRACK CAPITAL, LP
5.31501%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
4.85253%
KYNAM CAPITAL MANAGEMENT, LP
KYNAM CAPITAL MANAGEMENT, LP
...

Vera Therapeutics Beneficial Ownership Filings (SEC 13D/G)

Free Float
81.5%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
15.10%
Patrick G. Enright
Patrick G. Enright
SEC ↗
15.10%
Longitude Venture Partners IV, L.P.
Longitude Venture Partners IV, L.P.
SEC ↗
15.10%
Longitude Capital Partners IV, LLC
Longitude Capital Partners IV, LLC
SEC ↗
15.10%
Juliet Tammenoms Bakker
Juliet Tammenoms Bakker
SEC ↗
14.60%
98-0518585
98-0518585
SEC ↗
14.50%
Sofinnova Management X, L.L.C. (“SM X”)
Sofinnova Management X, L.L.C. (“SM X”)
SEC ↗
14.50%
Dr. Michael F. Powell (“Powell”)
Dr. Michael F. Powell (“Powell”)
SEC ↗
8.99%
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
SEC ↗
8.99%
KGaA, Darmstadt, Germany
KGaA, Darmstadt, Germany
SEC ↗
8.99%
Ares Trading SA
Ares Trading SA
SEC ↗

Vera Therapeutics Executives and Management Board

14 members · avg. age 57 · 29 % women

JC

Mr. Jason Carter (49)

Chief Legal Officer

5.65 M USD

Management

MF

Dr. Marshall Fordyce (51)

President, Chief Executive Officer, Founder, Director · since 2016

5.65 M USD
RB

Dr. Robert Brenner (57)

Chief Medical Officer

4.46 M USD
SG

Mr. Sean Grant (40)

Chief Financial Officer

1.76 M USD
DJ

Mr. David Johnson (55)

Chief Operating Officer

–
WT

Mr. William Turner (59)

Chief Development Officer

–

Board of Directors

CO

Ms. Christy Oliger (55)

Independent Director

775,395.00 USD
MM

Dr. Michael Morrissey (64)

Independent Chairman of the Board

471,589.00 USD
SM

Mr. Scott Morrison (67)

Independent Director

446,589.00 USD
PE

Mr. Patrick Enright (63)

Independent Director

438,589.00 USD
AC

Dr. Andrew Cheng (58)

Independent Director

437,589.00 USD
MK

Dr. Maha Katabi (51)

Independent Director

436,589.00 USD

Frequently asked questions about Vera Therapeutics

Analysts currently set an average price target of 76.42 USD for the Vera Therapeutics stock (median: 74.46 USD), implying +136.8 % versus the latest price. The consensus is based on 20 analyst ratings.

Vera Therapeutics Analyst Price Targets 2026

20 analysts currently rate the Vera Therapeutics stock: 17 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Vera Therapeutics to generate revenue of 25.55 M USD and earnings per share of -6.82 USD.

Vera Therapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the Vera Therapeutics share trades at 27.63 EUR (32.28 USD).

The Vera Therapeutics share (VERA) is listed on 1 stock exchanges, including: NASDAQ (VERA).

No history available for Vera Therapeutics.

The expected revenue of Vera Therapeutics is 25.55 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Vera Therapeutics is -437.83 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Vera Therapeutics is currently -4.74. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Vera Therapeutics stock.

The price-to-sales ratio (P/S) of Vera Therapeutics is currently 81.13. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Vera Therapeutics stock.

The Eulerpool Quality Score for Vera Therapeutics is 2/10.

The ISIN of Vera Therapeutics is US92337R1014. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Vera Therapeutics is VERA. The ticker symbol is used to trade Vera Therapeutics shares on the stock exchange.

Vera Therapeutics paid dividends every year for the past 0 years.

Vera Therapeutics is assigned to the 'Health' sector.

The dividends of Vera Therapeutics are distributed in USD.

All fundamentals and in-depth analysis of Vera Therapeutics

Our stock analysis for Vera Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vera Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Vera Therapeutics Stock
Vera Therapeutics Revenue→
Vera Therapeutics Stock
Vera Therapeutics Net Income→
Vera Therapeutics Stock
Vera Therapeutics P/E→
Vera Therapeutics Stock
Vera Therapeutics P/S→
Vera Therapeutics Stock
Vera Therapeutics EBIT→
Vera Therapeutics Stock
Vera Therapeutics Dividend→
Vera Therapeutics Stock
Vera Therapeutics Directors Dealings→
Vera Therapeutics Stock
Vera Therapeutics Stocks→
Vera Therapeutics Stock
Vera Therapeutics Market capitalization→
Vera Therapeutics Stock
Vera Therapeutics Debt→
Vera Therapeutics Stock
Vera Therapeutics Liabilities→
Vera Therapeutics Stock
Vera Therapeutics Equity→
Vera Therapeutics Stock
Vera Therapeutics AAQS→
Vera Therapeutics Stock
Vera Therapeutics Employees→
Vera Therapeutics Stock
Vera Therapeutics ROE→
Vera Therapeutics Stock
Vera Therapeutics ROA→
Vera Therapeutics Stock
Vera Therapeutics ROCE→
Vera Therapeutics Stock
Vera Therapeutics News→
Vera Therapeutics Stock
Vera Therapeutics Analyst Price Targets→

Health Stocks

VeracyteVenus RemediesVeradigmVenus Medtech HangzhouVerastemVentriPoint DiagnosticsVericelVeeva SystemsVerisante TechnologyVeerhealth CareVerrica PharmaceuticalsVectus BiosystemsAll Stocks A–Z →